

# Nathan R Hill

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1402558/publications.pdf>

Version: 2024-02-01

44  
papers

3,902  
citations

361296

20  
h-index

243529

44  
g-index

46  
all docs

46  
docs citations

46  
times ranked

7486  
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of undiagnosed atrial fibrillation using a machine learning risk-prediction algorithm and diagnostic testing (PULsE-AI) in primary care: a multi-centre randomized controlled trial in England. <i>European Heart Journal Digital Health</i> , 2022, 3, 195-204.	0.7	8
2	Identification of undiagnosed atrial fibrillation using a machine learning risk prediction algorithm and diagnostic testing (PULsE-AI) in primary care: cost-effectiveness of a screening strategy evaluated in a randomized controlled trial in England. <i>Journal of Medical Economics</i> , 2022, 25, 974-983.	1.0	7
3	Detecting undiagnosed atrial fibrillation in UK primary care: Validation of a machine learning prediction algorithm in a retrospective cohort study. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 598-605.	0.8	32
4	Using machine learning to predict anticoagulation control in atrial fibrillation: A UK Clinical Practice Research Datalink study. <i>Informatics in Medicine Unlocked</i> , 2021, 25, 100688.	1.9	7
5	Self-monitoring of Blood Pressure in Patients With Hypertension-Related Multi-morbidity: Systematic Review and Individual Patient Data Meta-analysis. <i>American Journal of Hypertension</i> , 2020, 33, 243-251.	1.0	46
6	A Systematic Review of Network Meta-Analyses and Real-World Evidence Comparing Apixaban and Rivaroxaban in Nonvalvular Atrial Fibrillation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602961989876.	0.7	15
7	Cost-effectiveness of targeted screening for the identification of patients with atrial fibrillation: evaluation of a machine learning risk prediction algorithm. <i>Journal of Medical Economics</i> , 2020, 23, 386-393.	1.0	15
8	Identification of undiagnosed atrial fibrillation patients using a machine learning risk prediction algorithm and diagnostic testing (PULsE-AI): Study protocol for a randomised controlled trial. <i>Contemporary Clinical Trials</i> , 2020, 99, 106191.	0.8	14
9	Application of a machine learning algorithm for detection of atrial fibrillation in secondary care. <i>IJC Heart and Vasculature</i> , 2020, 31, 100674.	0.6	8
10	Updated Software for Automated Assessment of Glucose Variability and Quality of Glycemic Control in Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 701-708.	2.4	22
11	Assessment of Glucose Control Metrics by Discriminant Ratio. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 719-726.	2.4	22
12	Prevalence of chronic kidney disease in the community using data from OxRen: a UK population-based cohort study. <i>British Journal of General Practice</i> , 2020, 70, e285-e293.	0.7	37
13	Trends in kidney function testing in UK primary care since the introduction of the quality and outcomes framework: a retrospective cohort study using CPRD. <i>BMJ Open</i> , 2019, 9, e028062.	0.8	11
14	Predicting atrial fibrillation in primary care using machine learning. <i>PLoS ONE</i> , 2019, 14, e0224582.	1.1	88
15	Anticoagulant selection for patients with VTE—Evidence from a systematic literature review of network meta-analyses. <i>Pharmacological Research</i> , 2019, 143, 166-177.	3.1	17
16	Evolution of the burden of active hepatitis C virus infection in England from September 2015 to September 2016: a repeated cross-sectional analysis. <i>BMJ Open</i> , 2019, 9, e029066.	0.8	2
17	A systematic review of network meta-analyses among patients with nonvalvular atrial fibrillation: A comparison of efficacy and safety following treatment with direct oral anticoagulants. <i>International Journal of Cardiology</i> , 2018, 269, 174-181.	0.8	39
18	The Journal of Comorbidity Affiliates with the Society for Academic Primary Care. <i>Journal of Comorbidity</i> , 2016, 6, 73-75.	3.9	2

#	ARTICLE	IF	CITATIONS
19	Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis. PLoS ONE, 2016, 11, e0158765.	1.1	2,336
20	A Metabolic Study of Huntington’s Disease. PLoS ONE, 2016, 11, e0146480.	1.1	41
21	A 24-Hour Study of the Hypothalamo-Pituitary Axes in Huntington’s Disease. PLoS ONE, 2015, 10, e0138848.	1.1	22
22	Preventing delirium: should non-pharmacological, multicomponent interventions be used? A systematic review and meta-analysis of the literature. Age and Ageing, 2015, 44, 196-204.	0.7	145
23	Low Circulating Levels of IGF-1 in Healthy Adults Are Associated With Reduced $\beta$ -Cell Function, Increased Intramyocellular Lipid, and Enhanced Fat Utilization During Fasting. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2198-2207.	1.8	39
24	Investigating the sustainability of careers in academic primary care: a UK survey. BMC Family Practice, 2014, 15, 205.	2.9	5
25	Plasma melatonin is reduced in Huntington’s disease. Movement Disorders, 2014, 29, 1511-1515.	2.2	81
26	Deconvolution analysis of 24h serum cortisol profiles informs the amount and distribution of hydrocortisone replacement therapy. Clinical Endocrinology, 2013, 78, 347-351.	1.2	27
27	The Oxford Renal (OxRen) cross-sectional study of chronic kidney disease in the UK. BMJ Open, 2013, 3, e004265.	0.8	7
28	Cyclical Variation in HbA1c Values During the Year: Clinical and Research Implications. Diabetes Care, 2013, 36, e175-e176.	4.3	9
29	Expansion of the Homeostasis Model Assessment of $\beta$ -Cell Function and Insulin Resistance to Enable Clinical Trial Outcome Modeling Through the Interactive Adjustment of Physiology and Treatment Effects: iHOMA2. Diabetes Care, 2013, 36, 2324-2330.	4.3	92
30	Maternal hyperinsulinism and glycaemic status in the first trimester of pregnancy are associated with the development of pregnancy-induced hypertension and gestational diabetes. European Journal of Endocrinology, 2013, 168, 413-418.	1.9	20
31	Methodology for Quantifying Fasting Glucose Homeostasis in Type 2 Diabetes: Observed Variability and Lability. Journal of Diabetes Science and Technology, 2013, 7, 640-645.	1.3	3
32	Proliferation Rates of Multiple Endocrine Neoplasia Type 1 (MEN1)-Associated Tumors. Endocrinology, 2012, 153, 5167-5179.	1.4	13
33	The effect of prolonged fasting on levels of growth hormone-binding protein and free growth hormone. Growth Hormone and IGF Research, 2012, 22, 76-81.	0.5	9
34	Normal Reference Range for Mean Tissue Glucose and Glycemic Variability Derived from Continuous Glucose Monitoring for Subjects Without Diabetes in Different Ethnic Groups. Diabetes Technology and Therapeutics, 2011, 13, 921-928.	2.4	279
35	Conference Scene: Conference report on the 4th Annual International Conference on Advanced Technologies & Treatments for Diabetes. Diabetes Management, 2011, 1, 269-270.	0.5	0
36	Sleep apnea predicts distinct alterations in glucose homeostasis and biomarkers in obese adults with normal and impaired glucose metabolism. Cardiovascular Diabetology, 2010, 9, 83.	2.7	39

#	ARTICLE	IF	CITATIONS
37	Effects of prolonged fasting and sustained lipolysis on insulin secretion and insulin sensitivity in normal subjects. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2009, 296, E454-E461.	1.8	38
38	Validation of Continuous Glucose Monitoring in Children and Adolescents With Cystic Fibrosis. <i>Diabetes Care</i> , 2009, 32, 1020-1022.	4.3	92
39	Glycaemic risk assessment in children and young people with Type 1 diabetes mellitus. <i>Diabetic Medicine</i> , 2009, 26, 740-743.	1.2	12
40	The Pregnancy-Induced Increase in Baseline Circulating Growth Hormone in Rats is not Induced by Ghrelin. <i>Journal of Neuroendocrinology</i> , 2008, 20, 309-322.	1.2	22
41	Higher body mass index is associated with irregular and suppressed insulin pulsatility. <i>Diabetes, Obesity and Metabolism</i> , 2007, 9, 603-604.	2.2	2
42	A method for assessing quality of control from glucose profiles. <i>Diabetic Medicine</i> , 2007, 24, 753-758.	1.2	108
43	Pioglitazone and metformin. <i>Drugs of Today</i> , 2007, 43, 443.	0.7	5
44	A Homozygous R262Q Mutation in the Gonadotropin-Releasing Hormone Receptor Presenting as Constitutional Delay of Growth and Puberty with Subsequent Borderline Oligospermia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 5117-5121.	1.8	62